Iambic Therapeutics, a drug developer backed by Nvidia and Qatar’s sovereign wealth fund, has filed for a U.S. initial public offering, adding another biotechnology company to an increasingly active fall pipeline and highlighting the sector’s relative resilience as other parts of the IPO market face rising borrowing costs and geopolitical uncertainty.
The San Diego-based company filed on Monday after two other drug developers, Retension Pharmaceuticals and TRex Bio, submitted IPO paperwork on Friday. ADARx Pharmaceuticals also began its roadshow on Monday, adding to a cluster of biotech listings and planned offerings.
The activity stands out against a more difficult backdrop for new stock offerings. The fall IPO market has faced uncertainty linked to the Iran war, higher bond yields, interest-rate increases, and concerns about how artificial intelligence could disrupt established industries.
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Biotech has been less exposed to those pressures, according to IPO analysts, helped in part by continued acquisition activity from large pharmaceutical companies seeking new drugs and promising clinical programs.
“All five of the year’s best-performing IPOs ($50 million deal size and above) are biotechs. Much of that is being driven by drug advancement and M&A,” said Matt Kennedy, senior strategist at Renaissance Capital, which tracks IPOs and manages IPO-focused funds.
Iambic’s offering adds another dimension to the biotech boom because the company is built around the use of artificial intelligence in drug discovery.
Founded in 2019 as Entos, Iambic is developing drug candidates for solid tumors using an AI platform designed to accelerate the discovery of small-molecule therapies. Its most advanced candidate, IAM1363, is being tested in an early-stage clinical trial for solid tumors including breast cancer. The program remains at an early stage, meaning investors will ultimately have to assess the company’s value against the substantial clinical and regulatory risks associated with drug development.
The IPO filing comes on the same day that Iambic announced a multi-year collaboration with AbbVie to accelerate AI-driven discovery of small-molecule medicines.
The agreement expands a partnership network that already includes Takeda, Lundbeck, Revolution Medicines, Jazz Pharmaceuticals and Bayer. The breadth of those relationships provides Iambic with commercial validation for its drug-discovery platform, although partnerships do not guarantee that experimental medicines will successfully reach the market.
Iambic has raised about $461.8 million from technology and healthcare investors since its founding. Its backers include Nvidia and Qatar Investment Authority, alongside Catalio, Nexus Ventures and Coatue Management.
Nvidia’s involvement is notable because the chipmaker has become one of the central financial and technological beneficiaries of the AI boom. Its investment in Iambic extends that exposure beyond computing infrastructure into an industry where AI is being used to shorten parts of the drug-development process.
For investors, that creates a potentially attractive but difficult proposition. AI can help pharmaceutical researchers process biological data, identify potential compounds and improve parts of the drug-discovery workflow, but the technology does not remove the lengthy clinical testing and regulatory process that determines whether a drug can become commercially viable.
Iambic’s most advanced program therefore remains the critical factor for public-market investors. A successful clinical development path could give the company significant value, while disappointing results could quickly undermine the investment case.
The timing of the IPO also matters. Biotechnology companies have historically been sensitive to financing conditions because many developers operate for years before generating meaningful product revenue. Higher interest rates can therefore increase the cost of capital and make speculative growth companies less attractive.
Yet the current biotech IPO pipeline suggests investors remain willing to fund companies with promising clinical programs, particularly where there is a credible path to acquisition by larger pharmaceutical companies. That acquisition backdrop has become more relevant for the sector. Large drugmakers face pressure to replenish pipelines as existing products mature, creating demand for smaller biotechnology companies with promising therapies and technology platforms.
Iambic is attempting to position itself at the intersection of those trends. Its partnerships give it access to established pharmaceutical companies, while its AI platform offers exposure to a technology theme that has attracted enormous investment across the broader economy.
The company’s decision to pursue a public listing also comes after substantial private-market funding. The roughly $462 million it has raised since inception gives Iambic a significant financial base, but the IPO will provide additional capital to advance its clinical pipeline and expand its drug-discovery operations.
Iambic plans to list on the Nasdaq under the ticker “IAM.” J.P. Morgan, Jefferies, BofA Securities and Citigroup are serving as underwriters.
The offering will provide another test of whether investors are willing to assign public-market valuations to AI-enabled biotechnology companies before their leading drug candidates have reached late-stage clinical development.
For the broader IPO market, Iambic’s filing adds to evidence that the reopening of the U.S. listing window is uneven rather than uniform. Companies tied to sectors with identifiable acquisition demand or differentiated technology are finding investors even as higher yields and geopolitical risks make capital markets more selective.